Details

Autor(en) / Beteiligte

• Işıkdoğan, A.
• Akdeniz, N.
• Küçüköner, M.
• Kaplan, M.A.
• Urakçı, Z.
• Karhan, O.
• Sezgin, Y.
• Bilen, E.
• Ebinç, S.
• Teke, F.
• Laçin, Ş
• Alan, O.
• Ercelep, O.
• Yumuk, F.

Titel

1464P - Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer

Ist Teil von

• Annals of oncology, 2019-10, Vol.30, p.v595-v595

Ort / Verlag

Elsevier Ltd

Erscheinungsjahr

2019

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• The optimal chemotherapy regimen for concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) remains unclear. Cisplatin-etoposide regimen related toxicity is high, weekly regimens have been investigating. We aimed to compare the efficacy and safety of different concurrent chemotherapy regimens in the context. A total of 225 patients with locally advanced, unresectable stage III NSCLC included. Patients who treated with weekly docetaxel-platin (DP), paclitaxel-platin (PP) and standard dose etoposide-platin (EP) chemotherapy regimens were selected and divided to groups for the comparison of toxicity, response rate, progression free survival (PFS) and overall survival (OS) rates. There was statistically significant difference between overall response rate of each treatment groups (DP: 96,1%, PP: 94% and EP:76.7%, p<0.001). The median PFS rate of patients who treated with DP, PP and EP was 16, 15 and 13.3 months, respectively (p=0.435). The median OS of patients treated with DP, PP and EP was 19.2, 29.7 and 28.3 months, respectively (p=0.092). The rates of adverse events such as nausea, vomiting, neuropathy and anaphylaxis was similar. Grade 1-2 mucositis or esophagitis, anemia, pneumonitis were significantly higher in PP group than other groups. However, hematologic toxicities were higher in the EP group than other groups.Table1464PTablePatients characteristicsDP (N=102) N(%)PP (N=50) N(%)EP (N=73) N(%)PMedian age6164580.038Gender Male93(91.2)48(96)64(87.7)0.28Histopathology Squamous cell53(52)31(62)43(58.9)<0.001Stage IIIB-IIIC65(63.7)31(62)41(56.2)0.59 When the weekly chemotherapy regimens were compared with the standard dose, our study demonstrated similar survival rates but better treatment response rates. Adverse events and toxicity rates were different and depending on the type of chemotherapy regimen used. Abdurrahman Işıkdogan. Has not received any funding. All authors have declared no conflicts of interest.